Treatment of Advanced Hepatocellular Carcinoma with Biweekly High-Dose Gemcitabine

Publisher： Karger

E-ISSN： 1423-0232|60|4|313-315

ISSN： 0030-2414

Source： Oncology, Vol.60, Iss.4, 2001-06, pp. : 313-315

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 65, Iss. 3, 2003-12 ,pp. : 242-249

Karger

Access to resources Recommend Favorite

Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 119-125

Karger

Access to resources Recommend Favorite

Efficacy and Tolerability of Low-Dose Thalidomide as First-Line Systemic Treatment of Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 72, Iss. 1, 2007-12 ,pp. : 67-71

Karger

Access to resources Recommend Favorite

A Dose Escalation Study of Biweekly Oral Vinorelbine and Gemcitabine in Patients with Solid Tumors

By  

Oncology, Vol. 71, Iss. 5-6, 2007-09 ,pp. : 347-353

Karger

Access to resources Recommend Favorite

Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 8, 2018-04 ,pp. : 1671-1675

John Wiley & Sons Inc

Access to resources Recommend Favorite